In 1994 was created Sanofi-Genzyme BioVentures, which is appeared as VC. The fund was located in North America if to be more exact in United States. Sanofi-Genzyme BioVentures appeared to be a CVC structure as part of the corporation. The leading representative office of defined VC is situated in the Cambridge.
The average startup value when the investment from Sanofi-Genzyme BioVentures is 100-500 millions dollars. The increased amount of exits for fund were in 2017. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund. Opposing the other organizations, this Sanofi-Genzyme BioVentures works on 3 percentage points more the average amount of lead investments.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Sanofi-Genzyme BioVentures, startups are often financed by New Enterprise Associates, GE Ventures, U.S. Venture Partners (USVP). The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Novartis Venture Fund, Atlas Venture. In the next rounds fund is usually obtained by Wellington Management, Rock Springs Capital, RA Capital Management.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Omada Health, Expansion Therapeutics, Evidation Health.
The overall number of key employees were 4.
|7 Industries||Netherlands, Noord-Holland, North Holland|
|Aries Capital Partners||Salt Lake City, United States, Utah|
|Camel Group||China, Hubei, Xiangyang|
|Cypherpunk Holdings Inc.||Canada, Ontario, Toronto|
|ETH Zurich Foundation||Switzerland, Zürich, Zurich|
|Silversmith Capital Partners||Boston, Massachusetts, United States|
|Wasatch Funds||Sandy, United States, Utah|
|$103M||27 Apr 2022||Oxford, England, United Kingdom|
|$33M||22 Mar 2022||Tel Aviv-Yafo, Tel Aviv District, Israel|
|$52M||22 Oct 2021||New York, New York, United States|
|$80M||21 Oct 2021||Dallas, Texas, United States|
|$80M||29 Sep 2021||San Diego, California, United States|
|$77M||14 Sep 2021||Cambridge, Massachusetts, United States|
|$73M||09 Jul 2021||Copenhagen, Hovedstaden, Denmark|
|$35M||23 Jun 2021||San Francisco, California, United States|
|$16M||16 Jun 2021||Frederick, Maryland, United States|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.